PTC Therapeutics, Inc. PTCT 深 滬
已收盤 02-06 16:00:00 美东时间
74.68
+2.320
+3.21%
華盛通- 最 高75.00
- 今 開73.77
- 成交量 104.05万股
- 最 低 72.64
- 昨 收 72.36
- 總市值 59.96亿
- 52周最高 87.50
- 市盈率 靜 --
- 換手率 1.30%
- 52周最低 35.95
- 委 比 57.09%
- 總股本 8028.83万
- 歷史最高 87.50
- 量 比 0.83
- 振 幅 3.26%
- 歷史最低 4.03
- 每 手 1
- 風險率 12.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多U.S. RESEARCH ROUNDUP-AGNC Investment, Brown & Brown, Korro Bio
U.S. RESEARCH ROUNDUP-AGNC Investment, Brown & Brown, Korro Bio Jan 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AGNC Investment, Brown & Brown and Korro Bio, on Thursday. HIGHLIGHTS * AGNC Investment Corp AGNC.O :
01-29 15:54
美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
Barclays Upgrades PTC Therapeutics to Overweight, Raises Price Target to $119
Barclays analyst Eliana Merle upgrades PTC Therapeutics (NASDAQ:PTCT) from Equal-Weight to Overweight and raises the price target from $68 to $119.
01-28 22:48
PTC Therapeutics Posts Strong 2025 Results, Updates 2026 Outlook
PTC Therapeutics ( ($PTCT) ) has issued an announcement. On January 12, 2026, P...
01-13 01:29
PTC Therapeutics projects FY26 product revenue between $700M to $800M
PTC Therapeutics (PTCT) on Monday reported unaudited 2025 product and royalty revenue of ~$823.4 million, exceeding guidance, and unaudited 2025 product revenue of ~$587.8 million. PTC expects to repo...
01-13 00:09
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
– Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M – – Unaudited 2025 total product and royalty revenue of approximately $823M, exceeding guidance ...
01-12 21:30
Royalty Pharma Acquires The Final Portion Of PTC Therapeutics' Remaining Royalty On Roche's Evrysdi For $240M Upfront And Up To $60M In Sales-based Milestones
Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 million upfront and up to $60 million in sales-based
2025-12-30 05:43
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
Royalty Pharma has acquired PTC Therapeutics’ remaining royalty on Roche’s Evrysdi for $240 million upfront and up to $60 million in sales-based milestones. Evrysdi, an oral treatment for spinal muscular atrophy, has treated over 21,000 patients globally, with 2024 sales of $1.9 billion and projected to reach $2.9 billion by 2030. Royalty Pharma will now own 100% of the tiered 8% to 16% royalty, with payments increasing based on sales thresholds....
2025-12-29 21:40
Japanese Regulator Approves PTC Therapeutics' Sephience (Sepiapterin) For Phenylketonuria. The Label Includes Individuals Of All Ages And The Full Spectrum Of Disease Severity
PTC will now engage in pricing discussions which are expected to conclude in Q1 2026, with launch occurring shortly thereafter. First Japan product approval for PTC
2025-12-22 20:08
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Dec. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 16, 2025, the company approved non-statutory stock options to purchase an aggre...
2025-12-20 05:30
